Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Equity Capital Markets

Mabwell (Shanghai) Bioscience / Equity Capital Markets

<ul>
<li>Mabwell, a China-based biotech, launched its IPO to raise at least USD 185 million via a Hong Kong listing.</li>
<li>In this note, we look at the deal terms and provide our thought of valuation for the company.</li>
<li>We analyzed the reference connect events and assess the risk-reward of the deal.</li>
</ul>


Mabwell, a China-based biotech, launched its IPO to raise at least USD 185 million via a Hong Kong listing.
In this note, we look at the deal terms and provide our thought of valuation for the company.
We analyzed the reference connect events and assess the risk-reward of the deal.


Shenzhen Zhaowei Machinery & Electronics (2692 HK)

Shenzhen Woer Heat-Shrinkable Material (9981 HK)

Mabwell (迈威生物) A+H: Moderate Upside but Connect Event Ahead